2-Deoxy-D-Glucose and its Derivatives for the COVID-19 Treatment: An Update

Zoufang Huang‡, Vivek P. Chavda†‡, Lalitkumar K. Vora†‡, Normi Gajjar4, Vasso Apostolopoulos5, Nirav Shah6 and Zhe-Sheng Chen7*

1Department of Hematology, Ganzhou Key Laboratory of Hematology, The First Affiliated Hospital of Gannan Medical University, Ganzhou, China, 2Department of Pharmaceutics and Pharmaceutical Technology, L M College of Pharmacy, Ahmedabad, India, 3School of Pharmacy, Queen’s University Belfast, Belfast, United Kingdom, 4PharmD Section, L.M. College of Pharmacy, Ahmedabad, India, 5Institute for Health and Sport, Victoria University, Melbourne, VIC, Australia, 6Department of Pharmaceutics, SAL Institute of Pharmacy, Ahmedabad, India, 7Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John’s University, New York City, NY, United States

MINI REVIEW

OPEN ACCESS

Edited by:
Ji-Ye Yin, Central South University, China

Reviewed by:
Imran Shair Mohammad, Erciyes University, Turkey

Guangjian Fan, Shanghai General Hospital, China

*Correspondence:
Vivek P. Chavda
Vivek7chavda@gmail.com

Lalitkumar K. Vora
L.Vora@qub.ac.uk
Zhe-Sheng Chen
chenz@stjohns.edu

ORCID:
Vivek P. Chavda orcid.org/0000-0002-7701-8897
Lalitkumar K. Vora orcid.org/0000-0001-8106-9066
Zhe-Sheng Chen orcid.org/0000-0001-8093-9247

‡These authors have contributed equally to this work and share first authorship

Specialty section:
This article was submitted to Experimental Pharmacology and Drug Discovery, a section of the journal Frontiers in Pharmacology

Received: 18 March 2022
Accepted: 28 March 2022
Published: 12 April 2022

Citation:
Huang Z, Chavda VP, Vora LK, Gajjar N, Apostolopoulos V, Shah N and Chen Z-S (2022) 2-Deoxy-D-Glucose and its Derivatives for the COVID-19 Treatment: An Update. Front. PharmacoL 13:899633. doi: 10.3389/fphar.2022.899633

Treatments choices for the “severe acute respiratory syndrome-related coronavirus-2 (SARS-CoV-2)” are inadequate, having no clarity on efficacy and safety profiles. Currently, no established intervention has lowered the mortality rate in the “coronavirus disease 2019 (COVID-19)” patients. Recently, 2-deoxy-D-glucose (2-DG) has evaluated as a polypharmacological agent for COVID-19 therapy owing to its influence on the glycolytic pathway, interaction with viral proteins, and anti-inflammatory action. In May 2020, the Indian drug regulatory authority approved 2-DG as an emergency adjunct therapy in mild to severe COVID-19 patients. Clinical studies of 2-DG corroborate that it aids in faster recovery of hospitalized patients and decreases supplemental oxygen. Herein, we describe the development process, synthesis, mechanism of viral eradication, and preclinical and clinical development of 2-DG and its derivatives as molecularly targeted therapeutics for COVID-19 treatment.

Keywords: 2-deoxy-D-glucose, 2-DG, COVID-19, coronavirus, SARS-CoV-2, glycolysis, targeted therapy

INTRODUCTION

The perilous life-threatening COVID-19 is associated with the SARS-CoV-2, which was first reported to have occurred in Wuhan, China, in November 2019 (Chavda et al., 2021a). The first case was registered by the “World Health Organization (WHO)” on 31 December 2019 (Adil et al., 2021; Chavda and Apostolopoulos, 2021). The outbreak was declared a global pandemic on 11 March 2020, and as of 19 March 2022, almost 462 million individuals have been infected resulting in 6.06 million deaths globally (WHO, 2022). The progression of the COVID-19 is summarized in the Figure 1 and the readers can get the details of the same from the work of Trougakos and Colleagues (Trougakos et al., 2021) and from the work of Anant Parasher (Parasher, 2021).

Health care providers and experts around the globe are searching for appropriate COVID-19 treatment regimens (Chavda et al., 2022a; Basu et al., 2022). The emergency use approved vaccines are also not totally effective against the emerging variant of SARS-CoV-2 (Chavda et al., 2021b; Chavda et al., 2021c; Chavda et al., 2021d; Chavda et al., 2021e; Chavda and Apostolopoulos, 2022a; Chavda and Apostolopoulos, 2022b; Chavda and Apostolopoulos, 2022c). Among the massive COVID-19 cases, nearly 90% of SARS-CoV-2 infected individuals may not need hospitalization and can be treated at home, depending upon the severity of the infection. However, a small number of
individuals (10%) may exhibit severe signs that necessitate hospitalization. Such cases can further complicate treatment options due to the onset of life-threatening conditions, e.g., "acute respiratory distress syndrome (ARDS)", which may further lead to multiple organ failure (Huang et al., 2020; Chavda and Apostolopoulos, 2021). Repurposing of established drugs for the treatment of multiple diseases has recently become a popular tactic because it employs risk-free compounds with known pharmacodynamic, preclinical, and pharmacokinetic profiles that can proceed directly to the late phase of clinical trials, allowing the development of drug processes to be effectively low-cost and faster (Chavda et al., 2021f; Chavda et al., 2022a; Basu et al., 2022). Given that SARS-CoV-2 is a viral disease, a small number of anti-viral medications are available (e.g., Remdesivir, an antiviral agent that was originally employed to treat hepatitis-C), which have already been repurposed into COVID-19 therapy. Nevertheless, a greater comprehension of COVID-19 pathobiology is needed to devise plans for prophylaxis and treatment. Table 1 summarizes the possible repurposed drugs for the COVID-19 management.

Novel SARS-CoV-2 variants are causing great concern owing to their ability to resist innate or vaccine-induced immunity as well as existing therapeutics (Chavda et al., 2021g; Chavda et al., 2022a; Chavda et al., 2022b). The delta plus variant seems to have some tolerance against monoclonal antibody combination therapy, which is the only clinical distinction from the delta variant (Chavda et al., 2021b; Chavda and Apostolopoulos, 2022b). Recently, the WHO has classified a new variant of concern (VOC) as omicron, which contains more than 52 mutations, 30 of which have been discovered in the viral spike protein alone (Chavda and Apostolopoulos, 2022a; Chavda and Apostolopoulos, 2022c). In recovered COVID patients, several rare diseases including mucormycosis, white fungus infection, happy hypoxia, and other systemic disorders (multiple organ failure, immune-oncological challenges, antiphospholipid syndrome, thrombosis, etc.) have been observed (Chavda and Apostolopoulos, 2021; Iqbal et al., 2021; Nalbandian et al., 2021).

In this mini review, we emphasize on the newly repurposed drug molecule 2-deoxy-D-glucose (2-DG) in the management of COVID-19.

TARGETING GLUCOSE METABOLISM FOR SARS-CoV-2

Even though COVID-19 and cancer are two entirely separate illnesses, the same treatment may be possible due to the similarity between the virus infected and cancer cells (Zhang et al., 2006). Viruses and cancer cells need a lot of energy as they multiply so quickly. Since glucose is the primary source of sugar in living
organisms, the replicating cells consume it quickly to survive and reproduce (Fadaka et al., 2017). SARS-CoV-2 pathogenicity and replication are dependent on glycolysis and glycosylation. Glucose provides energy to viral host cells as adenosine triphosphate (ATP) derived from glycolysis, and it also allows glycan formation, which aids in the development of glycoproteins during glycosylation (Bojkova et al., 2020). Viruses change the metabolism of host cells to provide optimum conditions for fast and effective reproduction and dissemination. One important example is the increased intake of critical nutrients such as glucose to promote mitochondrial signalling, i.e., aerobic glycolysis, a dominant mechanism of glucose metabolism and its by-products for biosynthetic reactions.

Research has demonstrated that SARS-CoV-2 infection causes a metabolic resetting of human monocytes in elevated glucose cultures and promotes viral replication and cytokine formation while impairing T cell responses. The follow-up event to this causes lung epithelial cell death and, at the mechanistic level, explains why diabetic patients are at an increased threat of developing severe COVID-19 (Codo et al., 2020). Excess sugar metabolism during prolonged hyperglycemia can facilitate SARS-CoV-2 invasion and propagation, as well as an aggravated immune response. SARS-CoV-2 pathogenesis is aided by an inherent cellular approach. As a result, these cells absorb a large volume of the compound 2-DG, an antimetabolite of glucose. The 2-DG drug, like glucose, distributes across the body and enters virus-infected cells, where it stops viral synthesis and kills the protein’s energy production, preventing virus development. Since the drug inhibits both glycolysis and

TABLE 1 | Drugs repurposed for COVID-19.

| Drug name                                         | Mechanism of action                                      | Registered Clinical trial no                     |
|---------------------------------------------------|----------------------------------------------------------|--------------------------------------------------|
| Small molecule                                    |                                                          |                                                  |
| Carragelose nasal spray (Marinomed Biotech)       | It creates a protective layer over host cell nasal mucosal membrane | NCT04590365, NCT046881001, NCT04521322, NCT04793984 |
| Chloroquine and hydroxychloroquine tablet         | Multiple pathways impede viral entry and endocytosis and host immunomodulatory effects | NCT04303507, NCT04860284 |
| Remdesivir injection (Gilead)                     | Inhibits RNA polymerases (RdRps)                         | NCT04315948, NCT04292730 |
| Favipiravir tablet                                | Inhibits RNA polymerases (RdRps)                         | NCT04694612, NCT04359615 |
| Apixaban tablet (NHLBI)                           | Inhibit upregulated COX2 in COVID 19                     | NCT04498273, NCT04650087, NCT04801940, NCT04746839, NCT04512079 |
| Icosapent ethyl tablet (Amarin Corporation)       | Anti-inflammatory agent                                  | NCT04412016, NCT04465065, NCT04505098 |
| Abiraterone injection (Sorrento Therapeutics)     | Tyrosine kinase inhibitors                               | NCT04440007, NCT04528967 |
| Ivermectin tablet                                 | Inhibiting the host importin alpha/beta-1 nuclear transport proteins | NCT04529625, NCT04438850, NCT04314166, NCT04703205 |
| Dexamethasone tablet and injection                | Anti-inflammatory agent                                  | NCT04640168, NCT04327401, NCT04695197 |
| Artesunate/pyronaridine tablet (Shin Poong Pharmaceutical Co., Ltd.) | Act on TLR4 inflammatory signaling pathway             | NCT044765107, NCT04532931, NCT04701606, NCT04695197 |
| Hydrocortisone tablet                             | Anti-inflammatory agent                                  | NCT04384305, NCT042517489 |
| Camostat mesylate tablet (Chugai Pharmaceuticals) | Serine protease inhibitor                               | NCT04668266, NCT04418128, NCT04527133 |
| Umifenovir tablet (Jiennig QU)                    | Inhibits the viral envelope’s membrane fusion           | NCT04350664 |
| Nitazoxanide tablet                               | Upregulates innate immunity and act on interferon pathway | NCT04685313, NCT04359680, NCT04343248, NCT04511819 |
| Ivermectin tablet (Revive Therapeutics Ltd.)     | Reduces upregulated C-reactive protein and IL-6 Immunomodulator | NCT04504734 |
| Nitric oxide inhalation (Bellerophon Therapeutics) | Inhibits viral replication via intermediate peroxynitrite pathway | NCT04421508 |
| Niclosamide nasal spray (Union therapeutics)     | It inhibits S-Phase kinase-associated protein-2         | NCT04603924, NCT04436458, NCT04749173, NCT04372082 |
| Large molecule                                     |                                                          |                                                  |
| Lenzilumab injection (Catalent)                   | Antagonize GM-CSF signaling                              | NCT04583966 |
| Canakinumab injection (Novartis)                  | IL-1β inhibitor and neutralizes IL-1β activity by blocking its interaction with its receptors | NCT04362813, NCT04365153 |
| Tocilizumab injection (Genentech)                 | Anti-IL-6 hence supports in cytokine storm              | NCT04320615, NCT04372186, NCT04409262, NCT04381936 |
| Leronlimab injection (CytoDyn)                    | CCR5 antagonist which causes the downstream release of proinflammatory cytokines | NCT04343651, NCT04347239 |
| Infliximab injection (Janssen)                    | TNF inhibitor                                           | NCT04593940 |
| Gimsilumab injection (Roivant Sciences)           | GM-CSF antagonist                                       | NCT04351243 |
| Adalimumab injection (Abbvie)                     | TNF inhibitor                                           | NCT04705844 |
| Recombinant human plasma (BioAegis Therapeutics)  | Suppress cytokine release syndrome                      | NCT04358406 |
| Lanadelumab injection (Takeda)                    | Bradykinin release blocker                              | NCT04460105 |
glycosylation, it slows virus development (Figure 2) (Sahu and Kumar, 2021).

As 2-DG has structural similarity with glucose, it binds and inhibits hexokinase - the key enzyme for glycolysis and energy production in the form of ATP. When hexokinase is inhibited, glycolysis and ATP production is suppressed, and the cell does not generate energy (Bojkova et al., 2021). Ultimately, the virus will not consume adequate energy due to the reduced energy production by the host cells, and this deprived cellular microenvironment leads to virus deactivation (Wang et al., 2015). Additionally, a reduced concentration of ATP activates the AMP (adenosine monophosphate) mediated protein kinase, followed by phosphorylation of mTOR kinase (the mechanistic target of rapamycin kinase) and tuberous sclerosis (TSC 1) (Aft et al., 2002). Thus, autophagy of virus-infected cells and cell death occurs because of the inhibition of the G1 phase in the cell cycle (Sottnik et al., 2011). Similarly, 2-DG inhibits SARS-CoV-2 multiplication in Caco-2 colon cancer cells, a common model used for the intestinal epithelial barrier (Bojkova et al., 2020).

GLUCOSE ANALOGUES FOR SARS-COV-2 TREATMENT

2-Deoxy-D-Glucose

2-DG (Figure 3) is a glucose molecule with hydrogen swapped for the 2-hydroxyl bonds, restricting further glycolysis. It functions at the level of phosphoglucoisomerase to impede the synthesis of glucose-6-phosphate from glucose (step 2 of glycolysis) (Wick et al., 1957). In the liver and kidneys, glucose hexokinase phosphorylates 2-DG, capturing the compound 2-
2-Deoxy-D-glucose and its Derivatives for COVID-19 Treatment

Molecular Docking and Synthesis Process

Molecular docking is often used to predict preferred orientations of one molecule in relation to another molecule and binding conformations of small drug ligands to a desired binding site or receptor (Lengauer and Rarey, 1996). Using such in silico methods, SARS-CoV-2 viral nuclease nsp15 endonuclease (PDB ID: 6VWW), main protease or 3CLpro (PDB ID: 1Q2W), and the spike glycoprotein (PDB ID: 6VSB) were used to determine interactions of the drugs lopinavir, favipiravir and hydroxychloroquine (Balkrisna et al., 2020). It was noted that 2-DG had a binding energy $-140.05$ kcal/mol with 3CLpro, which was superior to lopinavir ($-124.00$ kcal/mol). Similarly, the binding energy with endonuclease was $-168.65$ kcal/mol, which is superior to the drug favipiravir ($-128.00$ kcal/mol) and $-118.31$ kcal/mol with the spike glycoprotein. In addition, a derivative of 2-DG, namely 1, 3, 4, 6-Tetra-O-acetyl-2-deoxy-D-gluco.pyranose, was shown to have superior binding energies compared with lopinavir, favipiravir, and hydroxychloroquine. Further, 2-DG follows all Lipinski’s parameters as molecular properties of a drug in regards to bioavailability and drug likeness (Lipinski, 2004). Bioactivity analysis and toxicity studies suggest that the 2-DG and its derivative can produce sufficient oral bioavailability without any major side effects or toxicity (Balkrisna et al., 2020). The drug has 379 mg/ml water solubility and $-2 \log P$ value (Figure 4 Drugbank (2013).

For synthesizing 2-DG, Mereyala et al. performed haloalkoxylation of R-D-Glucal, where $R = H$ and 3, 4, 6-tri-O-benzyl. They obtained alkyl 2-deoxy-2-halo-R-$\alpha$/-$\beta$-D-gluco/mannopyranoside, which was further converted into alkyl 2-deoxy-2-halo-R-$\alpha$/$\beta$-D-gluco/mannopyranoside by reduction to alkyl 2-deoxy-2-$\alpha$/-$\beta$-D-glucopyranoside followed by hydrolyzation to alkyl 2-deoxy-$\alpha$/-$\beta$-D-gluco.pyranoside and to 2-DG (Figure 5 Mereyala and Kumar, 2014).

Preclinical and Clinical Development

2-DG is consumed by the SARS-CoV-2 contaminated cells. However, it is unclear whether 2-DG has the ability to destroy or damage normal cells or whether it has any effect at all on them. When weighing costs and advantages, the most critical question is whether the benefits outweigh the risks. On critical analysis, it can be stated that there are demonstrated benefits of 2-DG and that they outweigh the risks; hence, it is currently being provided to individuals with mild to severe COVID-19 infection. These patients have a significantly better chance of survival treated with 2-DG than people who receive traditional medications (The Indian Express, 2021).

"Defence Research and Development Organisation (DRDO)" took the lead in designing an anti-COVID-19 medicinal implementation of 2-DG. INMAS-DRDO scientists, with the assistance of the “Centre for Cellular and Molecular Biology (CCMB)”, Hyderabad, performed different lab experiments during the first wave of COVID-19 pandemic in April 2020 that showed 2-DG was effective against the SARS-CoV-2, inhibiting viral development (Business Standard, 2021). “Drug Controller General of India and Central Drugs Standard Control Organization approved Phase-II clinical trials of 2-DG in COVID-19 patients in May 2020. DRDO and its business
partner, Dr Reddy’s laboratories, have begun clinical trials to assess safety and effectiveness of 2-DG in COVID-19 patients (Figure 6) (The Indian Express, 2021).”

2-DG is stable in patients with COVID-19 and shows substantial progress in their rehabilitation in phase II clinical trials (including dose-ranging) performed from May to October 2020 (Ministry of Defence, 2021a; Ministry of Defence, 2021b). Phase IIa human clinical trials were conducted in 6 hospitals, whereas phase IIb clinical trials (dose-ranging) were conducted in 11 hospitals worldwide. A phase II study was carried out in 110 COVID-19 patients. In terms of effectiveness, those who were given 2-DG had a quicker symptomatic relief compared to those treated with standard of care (SOC) on a variety of endpoints (Ministry of Defence, 2021a; Ministry of Defence, 2021b). Comparing the median time for achieving normalization of basic vital sign factors to the SOC, a marginally favourable pattern (2.5 days difference) was observed. Based on the positive outcomes, DCGI approved phase III clinical trials in November 2020.
The phase III human clinical trial in 220 patients was conducted between December 2020 and March 2021 at 27 COVID-19 hospitals in the states of Uttar Pradesh, Delhi, Gujarat, West Bengal, Maharashtra, Rajasthan, Telangana, Andhra Pradesh, Tamil Nadu, and Karnataka. In comparison to SOC, a greater proportion of patients with in 2-DG arm proceeded symptomatically and many were free of mechanical ventilation reliance by day 3 (42 percent vs. 31 percent). An identical pattern was noted in the case of patients over the age of 65 (The Indian Express, 2021). Various potential side effects of 2-DG are reversible hyperglycemia, gastrointestinal bleeding, and QTc prolongation (Raez et al., 2013). Hyperglycemia may also worsen, particularly as the majority of COVID-19 patients are also on large dosages of steroids (Shah and Goel, 2021). The major loophole of the current phase II (n = 110) and Phase III (n = 220) clinical trial study data is very limited study population. Individuals with multi-organ dysfunction, ARDS, and those on mechanical ventilation were also omitted from the trial. Individuals with any type of chronic comorbidity were also barred from participating in the trial.

**THERANOSTIC ROLE OF 2-DG IN MANAGEMENT OF CYTOKINE STORM IN COVID-19**

2-DG has also proven to be a polypharmacological agent for COVID-19 therapy, due to its role in the glycolytic pathway, interaction with viral proteins, and anti-inflammatory activity (Dwarakanath and Jain, 2009; Thaker et al., 2019). Verma et al. conjectured that 2-DG could enhance the efficacy of low-dose radiation therapy (LDRT) in the treatment of COVID-19 pneumonia (Verma et al., 2020). Furthermore, the azido analogue of 2-DG, 2-azido-2-DG, has the ability to trigger catastrophic oxidative stress in a short time in severely ill COVID-19 patients (Verma et al., 2020).

Low dose radiation therapy can decrease the cytokine storm in COVID-19 patients owing to its capability to induce anti-inflammatory responses. Its pro-inflammatory assisted immune responses in patients infected with SARS-CoV-2 has been advocated to be an efficacious option for COVID-19 pneumonia therapy (Figure 7). Although, the timing of LDRT treatment is the most crucial factor as it may influence moderate versus severe conditions differentially. Appropriately, numerous LDRT protocols for COVID-19 patients are being evaluated with promising preliminary outcomes (Rödel et al., 2020; Wilson et al., 2020).

Because of the polypharmacological effects of 2-DG on infected lung cells, 2-DG could be a potential adjuvant to LDRT as it suppresses viral replication and thereby avoids damage to the lungs. It primarily includes suppressing the glycolysis (thus the energy status), changes in glycosylation of viral proteins, and regulation of inflammatory responses (cytokine storm). The combination can shield other vulnerable organs and tissues with subsequent reduction of death rate (Papineni et al., 2018). Still, rigorous studies on the optimization of dose and dosing frequency, as well as the assessment of associated toxicities, are needed.

**2-Deoxy-D-Glucose Prodrug (WP1122)**

Moleculin Biotech Inc., in collaboration with Texas University (United States), has synthesized and evaluated a 2-DG prodrug candidate, WP1122, and its analogs for COVID-19 treatment. The main reason behind using this prodrug approach was that 2-DG does not possess “drug-like properties” (Pajak et al., 2019). It metabolizes quickly (has a short half-life) and fails to provide the required concentration levels in organs and tissues. Principally, the achievement of sufficient concentration of 2-DG inside target organs and tissues to inhibit viral replication has not been possible in patients (Moleculin, 2021). Hence, WP112 with improved drug-like properties (Figure 8) is a promising analogue of 2-DG as a new anti-cancer agent, in addition to improving those with COVID-19.

This chemically modified 2-DG is transformed into pharmacologically active 2-DG in the body following administration (Figure 7). The scientists have already proven in vivo that WP1122 reaches a much higher concentration in tissues and organs compared to 2-DG alone. Interestingly, the level after WP1122 administration is nearly twice as much its half-life while the peak plasma concentration increases by almost three times. When 2-DG is delivered via WP1122, it provides a much higher concentration of 2-DG in the organs and tissues in vivo, as compared to when it is given directly (Zielinski, 2017). However, the greatest improvement seen is in the organ uptake and its potency. Moleculin Biotech’s previous work using WP1122 in cancer, even before the arrival of COVID-19, showed that WP1122 was 10 times more potent than equimolar doses of 2-DG alone. Recently, they have planned a clinical trial of WP1122 for COVID-19 (Stein et al., 2010; Zielinski, 2017).

**CONCLUSION**

Targeting glucose metabolism may offer new practical antiviral approaches for the treatment of mild to severe SARS-CoV-2
infection, especially in individuals with metabolic diseases. The 2-DG was designed to treat critically ill patients with COVID-19 in recent clinical trials in India. The Indian drug authority approved 2-DG as emergency use, which is available in powder form in sachets for oral route administration as an adjunct therapy. It builds up in virus-infected cells, prevents viral synthesis and energy output, and thereby inhibits viral replication. Its selective aggregation in the infected cells distinguishes this compound. Another promising approach is to use the combination of 2-DG and its derivative agents with different treatment modalities to inhibit the life cycle of the virus. This may slow down drug resistance development and decrease the effective concentration of individual drugs, reducing possible adverse effects. The findings are premature, and the individuals who will get 2-DG will need to be closely monitored. The creation of an online data repository to record the efficacy and adverse effects of 2-DG would be extremely beneficial in integrating data on 2-DG usage in COVID-19 illness. A multicentric investigation with a bigger population and from diverse geographical locations is needed to corroborate the preliminary results.

AUTHOR CONTRIBUTIONS

VC prepared the manuscript’s backbone and wrote the original draft of the manuscript along with ZH, NS, LV and NG. VC, Z-SC, LV and VA critically revised the manuscript for important intellectual content. VC and NG prepared figures. All authors have read and approved the final version. Figures were created with BioRender.Com.

ACKNOWLEDGMENTS

VC wants to dedicate this work to L M College of pharmacy as a part of the 75th year celebration of the college. The authors would like to acknowledge Prachi Bendale (School of Pharmacy, Queen’s University Belfast, United Kingdom) and Sita V. G., for peer-reviewing the manuscript and providing his valuable input to refine the manuscript. VA acknowledges the support of the Victoria University Planetary Health grant (PH098) and the Immunology and Translational research group, Victoria University, Australia.

REFERENCES

Adil, M. T., Rahman, R., Whitelaw, D., Jain, V., Al-Taan, O., Rashid, F., et al. (2021). SARS-CoV-2 and the Pandemic of COVID-19. Postgrad. Med. J. 97, 110–116. doi:10.1136/postgradmedj-2020-138386
Aft, R. L., Zhang, F. W., and Gius, D. (2002). Evaluation of 2-Deoxy-D-Glucose as a Chemotherapeutic Agent: Mechanism of Cell Death. Br. J. Cancer 87, 805–812. doi:10.1038/sj.bjc.6600547
Balkrishna, A., Thakur, P., Singh, S., Dev, S., Jain, V., Varshney, A., et al. (2020). Glucose Antimetabolite 2-Deoxy-D-Glucose and its Derivative as Promising Candidates for Tackling COVID-19: Insights Derived from In Silico Docking and Molecular Simulations. Author, 1–15. doi:10.22541/au.158567174.40895611

Business Standard (2021). DCGI Approves Anti-covid Drug Developed by DRDO for Emergency Use, Coronavirus Vaccine. Last Updated at May 8, 2021 15:31 IST. Available at: https://www.business-standard.com/article/current-affairs/dcgi-approves-anti-covid-drug-developed-by-drdo-for-emergency-use-121050800493_1.html (accessed May 24, 2021).
Clinical Complications. *J. Biomed. Sci.* 28, 9. doi:10.1186/s12929-020-00703-5

Verma, A., Adhikary, A., Woloschak, G., Dwarakanath, B. S., and Papineni, R. V. L. (2020). A Combinatorial Approach of a Polypharmacological Adjuvant 2-Deoxy-D-Glucose with Low Dose Radiation Therapy to Quell the Cytokine Storm in COVID-19 Management. *Int. J. Radiat. Biol.* 96, 1323–1328. doi:10.1080/09553002.2020.1818865

Wang, Z., Zhang, L., Zhang, D., Sun, R., Wang, Q., and Liu, X. (2015). Glycolysis Inhibitor 2-Deoxy-D-Glucose Suppresses Carcinogen-Induced Rat Hepatocarcinogenesis by Restricting Cancer Cell Metabolism. *Mol. Med. Rep.* 11, 1917–1924. doi:10.3892/mmr.2014.2945

WHO (2022). WHO Coronavirus (COVID-19) Dashboard, WHO Heal. Emerg. Dashboard. [https://covid19.who.int](https://covid19.who.int) (accessed March 19, 2022).

Wick, A. N., Drury, D. R., Nakada, H. L., and Wolfe, J. B. (1957). Localization of the Primary Metabolic Block Produced by 2-deoxyglucose. *J. Biol. Chem.* 224, 963–969. doi:10.1016/s0021-9258(18)64988-9

Wilson, G. D., Mehta, M. P., Welsh, J. S., Chakravarti, A., Rogers, C. L., and Fontanesi, J. (2020). Investigating Low-Dose Thoracic Radiation as a Treatment for COVID-19 Patients to Prevent Respiratory Failure. *Radiat. Res.* 194, 1–8. doi:10.1667/RADE-20-00108.1

Xi, H., Kurtoglu, M., Liu, H., Wangpaichitr, M., You, M., Liu, X., et al. (2011). 2-Deoxy-d-glucose Activates Autophagy via Endoplasmic Reticulum Stress rather Than ATP Depletion. *Cancer Chemother. Pharmacol.* 67, 899–910. doi:10.1007/s00280-010-1391-9

Zhang, X. D., Deslandes, E., Villedieu, M., Poulain, L., Duval, M., Gauduchon, P., et al. (2006). Effect of 2-Deoxy-D-Glucose on Various Malignant Cell Lines In Vitro. *Anticancer Res.* 26, 3561–3566.

Zielinski, R. (2017). “Preclinical Evaluation of WP1122, a 2-DG Prodrug and Inhibitor of Glycolysis,” in Symp. Cancer Res. 2017 Cancer Metab, Houston, TX, 10.

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher’s Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

**Copyright © 2022 Huang, Chavda, Vora, Gajjar, Apostolopoulos, Shah and Chen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.**